{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:53Z","timestamp":1786997933737,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.vaccine.2009.09.133","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T15:11:26Z","timestamp":1255533086000},"page":"494-511","source":"Crossref","is-referenced-by-count":67,"title":["Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates"],"prefix":"10.1016","volume":"28","author":[{"given":"Jay W.","family":"Hooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Silvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Alterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Rivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt I.","family":"Kamrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April (2)","key":"10.1016\/j.vaccine.2009.09.133_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(03)00008-1","article-title":"Pathogenesis and potential antiviral therapy of complications of smallpox vaccination","volume":"58","author":"Bray","year":"2003","journal-title":"Antiviral Res"},{"issue":"July (3)","key":"10.1016\/j.vaccine.2009.09.133_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1045-1870(03)00032-3","article-title":"Adverse events occurring after smallpox vaccination","volume":"14","author":"Lane","year":"2003","journal-title":"Semin Pediatr Infect Dis"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2009.09.133_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"Artenstein","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"March (6979)","key":"10.1016\/j.vaccine.2009.09.133_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2009.09.133_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2009.09.133_bib6","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.09.133_bib7","unstructured":"Hashizume S, Yoshizawa H, Morita M, Suzuki Kp-IGVQe, Vaccinia viruses as vectors for vaccine antigens. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Quainnan GV, editor. Vaccinia viruses as vectors for vaccine antigens. Amsterdam, Netherlands: Elsevier Science Publishing Co.; 1985. p. 421\u20138."},{"issue":"November (47\u201348)","key":"10.1016\/j.vaccine.2009.09.133_bib8","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: an attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2009.09.133_bib9","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.09.133_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/JVI.66.1.386-398.1992","article-title":"Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans","volume":"66","author":"Demkowicz","year":"1992","journal-title":"J Virol"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2009.09.133_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"issue":"October (19)","key":"10.1016\/j.vaccine.2009.09.133_bib12","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2009.09.133_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2009.09.133_bib14","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2009.09.133_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2009.09.133_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"issue":"February (10)","key":"10.1016\/j.vaccine.2009.09.133_bib17","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.vaccine.2006.11.017","article-title":"Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge","volume":"25","author":"Hooper","year":"2007","journal-title":"Vaccine"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2009.09.133_bib18","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1128\/JVI.00353-08","article-title":"Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice","volume":"82","author":"Kaufman","year":"2008","journal-title":"J Virol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.09.133_bib19","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1128\/JVI.65.10.5631-5635.1991","article-title":"The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals","volume":"65","author":"Lai","year":"1991","journal-title":"J Virol"},{"issue":"September (25\u201326)","key":"10.1016\/j.vaccine.2009.09.133_bib20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"issue":"November (2)","key":"10.1016\/j.vaccine.2009.09.133_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2009.09.133_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.virol.2007.01.001","article-title":"Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge","volume":"362","author":"Thornburg","year":"2007","journal-title":"Virology"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2009.09.133_bib23","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2005.08.010","article-title":"Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy","volume":"24","author":"Otero","year":"2006","journal-title":"Vaccine"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.09.133_bib24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination","volume":"16","author":"Roberts","year":"2008","journal-title":"Trends Microbiol"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2009.09.133_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virol.2008.04.003","article-title":"Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine","volume":"377","author":"Golden","year":"2008","journal-title":"Virology"},{"issue":"June (27\u201328)","key":"10.1016\/j.vaccine.2009.09.133_bib26","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","article-title":"Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies","volume":"26","author":"Golden","year":"2008","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2009.09.133_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20071854","article-title":"The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination","volume":"205","author":"Xu","year":"2008","journal-title":"J Exp Med"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2009.09.133_bib28","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1128\/JVI.78.13.7052-7060.2004","article-title":"Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses","volume":"78","author":"Snyder","year":"2004","journal-title":"J Virol"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2009.09.133_bib29","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2009.09.133_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/viro.2000.0546","article-title":"Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice","volume":"276","author":"Bernard","year":"2000","journal-title":"Virology"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2009.09.133_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2009.09.133_bib32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.virol.2006.10.049","article-title":"Alphavirus replicon approach to promoterless analysis of IRES elements","volume":"360","author":"Kamrud","year":"2007","journal-title":"Virology"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2009.09.133_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0042-6822(89)90347-4","article-title":"The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83","volume":"170","author":"Kinney","year":"1989","journal-title":"Virology"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.09.133_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"issue":"September (36)","key":"10.1016\/j.vaccine.2009.09.133_bib35","doi-asserted-by":"crossref","first-page":"12921","DOI":"10.1073\/pnas.0505180102","article-title":"Interferon function is not required for recovery from a secondary poxvirus infection","volume":"102","author":"Panchanathan","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2009.09.133_bib36","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/JVI.00115-06","article-title":"Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function","volume":"80","author":"Panchanathan","year":"2006","journal-title":"J Virol"},{"issue":"October","key":"10.1016\/j.vaccine.2009.09.133_bib37","article-title":"Correlates of protective immunity in poxvirus infection: where does antibody stand?","author":"Panchanathan","year":"2007","journal-title":"Immunol Cell Biol"},{"issue":"August","key":"10.1016\/j.vaccine.2009.09.133_bib38","article-title":"Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein","author":"Su","year":"2007","journal-title":"Virology"},{"issue":"November (48)","key":"10.1016\/j.vaccine.2009.09.133_bib39","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1016\/j.vaccine.2007.09.038","article-title":"Development and preclinical evaluation of an alphavirus replicon vaccine for influenza","volume":"25","author":"Hubby","year":"2007","journal-title":"Vaccine"},{"issue":"April (15)","key":"10.1016\/j.vaccine.2009.09.133_bib40","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","article-title":"Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges","volume":"25","author":"Fogg","year":"2007","journal-title":"Vaccine"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2009.09.133_bib41","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/JVI.70.6.3753-3762.1996","article-title":"Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene","volume":"70","author":"Roper","year":"1996","journal-title":"J Virol"},{"issue":"October (5693)","key":"10.1016\/j.vaccine.2009.09.133_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1101509","article-title":"SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus","volume":"306","author":"Newsome","year":"2004","journal-title":"Science (New York, NY)"},{"issue":"June","key":"10.1016\/j.vaccine.2009.09.133_bib43","article-title":"Characterization of chimpanzee\/human monoclonal antibodies to the vaccinia A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia mouse protection model","author":"Chen","year":"2007","journal-title":"J Virol"},{"issue":"November (21)","key":"10.1016\/j.vaccine.2009.09.133_bib44","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J Virol"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2009.09.133_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","article-title":"Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement","volume":"328","author":"Lustig","year":"2004","journal-title":"Virology"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2009.09.133_bib46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1006\/viro.1993.1302","article-title":"The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence","volume":"194","author":"Engelstad","year":"1993","journal-title":"Virology"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2009.09.133_bib47","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1128\/JVI.66.12.7217-7224.1992","article-title":"Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope","volume":"66","author":"Isaacs","year":"1992","journal-title":"J Virol"},{"issue":"April (15)","key":"10.1016\/j.vaccine.2009.09.133_bib48","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1073\/pnas.0601025103","article-title":"Ligand-induced and nonfusogenic dissolution of a viral membrane","volume":"103","author":"Law","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2009.09.133_bib49","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1073\/pnas.0701451104","article-title":"Smallpox subunit vaccine produced in Planta confers protection in mice","volume":"104","author":"Golovkin","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2009.09.133_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.2000.0750","article-title":"Antibody neutralization of the extracellular enveloped form of vaccinia virus","volume":"280","author":"Law","year":"2001","journal-title":"Virology"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2009.09.133_bib51","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R","volume":"79","author":"Aldaz-Carroll","year":"2005","journal-title":"J Virol"},{"issue":"February (6)","key":"10.1016\/j.vaccine.2009.09.133_bib52","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.0510598103","article-title":"Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2009.09.133_bib53","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1073\/pnas.97.4.1536","article-title":"A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site (IRES) and when present in linked multiple copies greatly enhances IRES activity","volume":"97","author":"Chappell","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"June (26)","key":"10.1016\/j.vaccine.2009.09.133_bib54","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1073\/pnas.0308759101","article-title":"Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells","volume":"101","author":"Chappell","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2009.09.133_bib55","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/JVI.01797-08","article-title":"Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement","volume":"83","author":"Benhnia","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.09.133_bib56","series-title":"Fields virology","first-page":"1249","article-title":"Poxviruses and their replication","author":"Moss","year":"2001"},{"issue":"August (1)","key":"10.1016\/j.vaccine.2009.09.133_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.09.133_bib58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1743-422X-6-28","article-title":"Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization","volume":"6","author":"Shinoda","year":"2009","journal-title":"Virol J"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2009.09.133_bib59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/JVI.61.2.395-404.1987","article-title":"A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers","volume":"61","author":"Rodriguez","year":"1987","journal-title":"J Virology"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2009.09.133_bib60","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1006\/viro.1995.1022","article-title":"Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins","volume":"206","author":"Grieder","year":"1995","journal-title":"Virology"},{"issue":"February (11\u201312)","key":"10.1016\/j.vaccine.2009.09.133_bib61","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0264-410X(01)00485-6","article-title":"Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses","volume":"20","author":"Balasuriya","year":"2002","journal-title":"Vaccine"},{"issue":"November (22)","key":"10.1016\/j.vaccine.2009.09.133_bib62","doi-asserted-by":"crossref","first-page":"10623","DOI":"10.1128\/JVI.74.22.10623-10630.2000","article-title":"Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles","volume":"74","author":"Balasuriya","year":"2000","journal-title":"J Virol"},{"issue":"November (1)","key":"10.1016\/j.vaccine.2009.09.133_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.vaccine.2009.09.133_bib64","doi-asserted-by":"crossref","first-page":"e2709","DOI":"10.1371\/journal.pone.0002709","article-title":"Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats","volume":"3","author":"Kamrud","year":"2008","journal-title":"PLoS ONE"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2009.09.133_bib65","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/339677","article-title":"Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon","volume":"185","author":"Lee","year":"2002","journal-title":"J Infect Dis"},{"issue":"August (1)","key":"10.1016\/j.vaccine.2009.09.133_bib66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"issue":"December (23)","key":"10.1016\/j.vaccine.2009.09.133_bib67","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J Virol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2009.09.133_bib68","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/CVI.00037-07","article-title":"Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins","volume":"14","author":"Reap","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2009.09.133_bib69","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2010","journal-title":"Vaccine"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2009.09.133_bib70","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/136.3.354","article-title":"Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine","volume":"136","author":"Burke","year":"1977","journal-title":"J Infect Dis"},{"issue":"March (4)","key":"10.1016\/j.vaccine.2009.09.133_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T21:23:48Z","timestamp":1590182628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09014935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0264410X09014935"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.133","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}